FDA 483 OBSERVATION · #130 OF 1,945 MOST-CITED

Specifications - labels, packaging

FDA cited this observation 238 times across 205 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Foods238
BY FISCAL YEAR
FY202641
FY202537
FY202421
FY202319
FY202218
FY20219
FY202017
FY201917
FY201822
FY201719
FY201618

What this observation means, and how to comply

SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.

21 CFR 211.122

Written procedures and specifications for the receipt, identification, examination, storage, handling, and approval or rejection of labeling and packaging materials are lacking or inadequate, as required by §211.122 — the controls that keep incorrect or unapproved labels and packaging out of finished drug product.

Why FDA writes it — Labeling and packaging errors are a leading cause of drug recalls and patient harm — a mislabeled product can deliver the wrong drug or strength. FDA protects against unexamined or uncontrolled labeling by requiring specifications and approval controls before any label reaches the line.

HOW TO COMPLY
  • Establish specifications and written procedures for receipt, examination, and approval or rejection of all labeling and packaging materials.
  • Examine incoming labeling against the approved specimen and quarantine until the quality unit approves it.
  • Control storage and issuance so obsolete or superseded labeling is destroyed and cannot be reissued.
  • Reconcile issued, used, and returned labeling for each batch to detect mix-ups or shortages.
WHY FIRMS GET CITED
  • Labeling is received and used without a documented examination against an approved master specimen.
  • Obsolete labels are not destroyed on a revision, so an outdated version is later pulled and applied.
PROFESSIONAL · REMEDIATION PLAYBOOK · SPEQ SYNTHESIS

How to close this finding — and stop it recurring

CHECKING ACCESS

Checking your access…

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 3.7× the rate of the average FDA-cited firm (28.8% vs 7.8%), across 205 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your access…

How FDA worded it — real examples

You did not establish label and packaging specifications.

Wand Packaging Inc. · Walnut, California · Foods · 2026-09-30

You did not establish label and packaging specifications.

Remedy's Health Food, Inc. · Key Largo, Florida · Foods · 2026-09-22

You did not establish label and packaging specifications.

TAKA USA, INC. · Coppell, Texas · Foods · 2026-09-16

You did not establish label and packaging specifications.

Ledj LLC · Aiken, South Carolina · Foods · 2026-09-04

You did not establish label specifications.

BioCorp Nutrition Labs · Melville, New York · Foods · 2026-09-02

You did not establish label and packaging specifications.

Ancient Formulas, Inc. · Wichita, Kansas · Foods · 2026-08-28

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Food industry →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →